Akebia Therapeutics (AKBA) Set to Announce Quarterly Earnings on Thursday

Akebia Therapeutics (NASDAQ:AKBA) will be announcing its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.04) per share for the quarter.

Akebia Therapeutics (NASDAQ:AKBA) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.02. The business had revenue of $43.65 million during the quarter, compared to the consensus estimate of $45.61 million. During the same quarter in the previous year, the company earned ($0.06) earnings per share. On average, analysts expect Akebia Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Akebia Therapeutics Price Performance

Akebia Therapeutics stock opened at $1.69 on Friday. The firm’s 50 day moving average price is $1.43 and its 200-day moving average price is $1.29. Akebia Therapeutics has a 1 year low of $0.80 and a 1 year high of $2.48. The stock has a market cap of $355.39 million, a P/E ratio of -8.05 and a beta of 0.77.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.50 target price on shares of Akebia Therapeutics in a report on Wednesday, October 23rd.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.